26 completed, 4 recruiting, 2 terminated, 2 unknown. 34 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 34 | Completed 26, Recruiting 4, Terminated 2, Unknown 2 |
| Phase 2 | 8 | Completed 7, Unknown 1 |
Follow Thromboembolism: new trials by email Literature Review of Thromboembolism trials Research Report on Thromboembolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of YKYY033 Injection YKYY033 Injection, YKYY033 Placebo - Venous Thromboembolism (VTE) | Phase 1 | Recruiting | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | 40 | 2026-07-10 | 2026-08-26 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism CITY-FXI, Placebo - Factor V Leiden, Prothrombin G20210A | Phase 1 | Recruiting | City Therapeutics | 182 | 2026-01-22 | 2026-11-09 |
| Excretion of Rivaroxaban in Human Breast Milk Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet - Postpartum, VTE Prophylaxis | Phase 1 | Recruiting | Thomas Jefferson University | 10 | 2025-07-01 | 2025-07-17 |
| A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 - Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers | Phase 1 | Completed | Bayer | 24 | 2024-10-10 | 2025-02-10 |
| A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion - Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers | Phase 1 | Completed | Bayer | 39 | 2024-09-18 | 2025-02-06 |
| Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis Rivaroxaban 10 mg Oral Tablet, Apixaban 2.5 mg Oral Tablet - Liver Cirrhosis | Phase 1 | Recruiting | Insel Gruppe AG, University Hospital Bern | 24 | 2021-05-19 | 2026-08-19 |
| Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome Dalteparin, Apixaban - Nephrotic Syndrome, Thromboembolic Disease | Phase 1 / Phase 2 | Completed | University of Aarhus | 57 | 2021-03-25 | 2025-04-11 |
| Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT Apixaban 2.5 MG Oral Tablet, Enoxaparin 40Mg/0.4mL Prefilled Syringe - Venous Thromboembolism | Phase 1 / Phase 2 | Completed | Stanford University | 82 | 2020-08-12 | 2025-06-22 |
| PET Fibrin Imaging of DVT and PE 64Cu-FBP8, PET-CT imaging - Pulmonary Embolism, Deep Vein Thrombosis | Phase 1 | Terminated | Peter Caravan | 6 | 2019-05-13 | 2026-03-18 |
| Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms Palbociclib, Rivaroxaban, SNP - Cancer, Solid Tumor | Phase 1 | Unknown | Lebanese University | 500 | 2019-02-01 | 2023-10-06 |
| A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers ONO-7684, ONO-7684 Placebo - Venous Thromboembolism | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 72 | 2019-01-17 | 2019-12-09 |
| Efficacy Comparison of Warfarin Versus Rivaroxaban CVT Rivaroxaban, Warfarin - Cerebral Venous Thrombosis | Phase 1 / Phase 2 | Unknown | Isfahan University of Medical Sciences | 50 | 2018-09-01 | 2018-11-20 |
| A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants Rivaroxaban (Xarelto, BAY59-7939) - Thromboembolic Disorders | Phase 1 | Completed | Bayer | 30 | 2017-07-05 | 2021-01-22 |
| Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus Apixaban alone, Cyclosporine, Tacrolimus - Venous Thromboembolism, Pharmacokinetics | Phase 1 | Completed | Thomas Jefferson University | 12 | 2017-04-18 | 2017-10-11 |
| Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants Apixaban, Clarithromycin - Venous Thromboembolism | Phase 1 | Completed | Bristol-Myers Squibb | 20 | 2016-09-01 | 2016-11-21 |
| Safety, Pharmacokinetics, Biodistribution, and Diagnostic Performance of [18F]GP1 PET in Thromboembolism [18F]GP1 - Thromboembolism | Phase 1 | Completed | Asan Foundation | 32 | 2016-08-04 | 2018-05-18 |
| Study to Evaluate Safety, PK and PD of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects EP=7041, Placebo - Arthroplasty, Replacement, Knee | Phase 1 | Completed | eXIthera Pharmaceuticals | 80 | 2016-07-01 | 2017-05-31 |
| Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism DS-1040b, Placebo, Enoxaparin - Pulmonary Embolism, Thrombotic Disease | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 134 | 2016-06-23 | 2023-04-19 |
| Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients Twice daily enoxaparin prophylaxis, Real time dose adjustment - Venous Thromboembolism, Deep Venous Thrombosis | Phase 1 | Completed | University of Utah | 118 | 2016-03-01 | 2018-10-19 |
| Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates Rivaroxaban (Xarelto, BAY59-7939) - Thromboembolism | Phase 1 / Phase 2 | Completed | Bayer | 10 | 2015-11-19 | 2018-07-10 |
Showing 20 of 34. Sign in to see all of them.
Venous Thromboembolism (22) · Pulmonary Embolism (8) · Venous Thrombosis (7) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Cardiovascular Diseases (2) · Colonic Neoplasms (2) · Embolism and Thrombosis (2) · Lung Neoplasms (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Brain Injuries, Traumatic (1) · Breast Feeding (1)
Vascular Diseases (33) · Cardiovascular Diseases (32) · Embolism and Thrombosis (32) · Lung Diseases (11) · Respiratory Tract Diseases (11) · Embolism (8) · Thrombosis (7) · Neoplasms by Site (5) · Pathological Conditions, Signs and Symptoms (5) · Digestive System Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Brain Diseases (3) · Central Nervous System Diseases (3)
apixaban (7) · Enoxaparin (6) · Rivaroxaban (6) · Tablets (3) · Dalteparin (2) · ALT-836 (1) · Clarithromycin (1) · Cyclosporine (1) · Drug Therapy (1) · Fondaparinux (1) · Gemcitabine (1) · Heparin, Low-Molecular-Weight (1) · Nitric Oxide (1) · Tacrolimus (1) · Warfarin (1)
Bayer (4) · Bristol-Myers Squibb (3) · Daiichi Sankyo (2) · Thomas Jefferson University (2) · Altor BioScience (1) · Asan Foundation (1) · Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (1) · BiO2 Medical (1) · CONKO-Studiengruppe (1) · City Therapeutics (1) · Insel Gruppe AG, University Hospital Bern (1) · Isfahan University of Medical Sciences (1) · Klein, Jeffrey A., M.D. (1) · Lebanese University (1) · McMaster University (1)
United States (18) · Canada (4) · Germany (4) · France (3) · Italy (3) · Spain (3) · United Kingdom (3) · Australia (2) · Austria (2) · Belgium (2) · China (2) · Israel (2) · Lebanon (2) · Mexico (2) · Netherlands (2)
Akihiko Taguchi, MD.PhD (1) · Arash Momeni, MD (1) · Bladimir Gil, MD (1) · Carlos Cadavid, MD (1) · Christopher Pannucci, MD MS (1) · Francisco Robert, M.D. (1) · Herb A Phelan, MD (1) · James J Czyrny, MD (1) · Jeff A Kline, MD (1) · Jennifer McNulty, MD (1)
PMID 40302153, PMID 24641937, PMID 26658126, PMID 29452956, PMID 29608533, PMID 29649055, PMID 30617563, PMID 31030414, PMID 31324209, PMID 31420317, PMID 33779986, PMID 36861188, PMID 40478760, PMID 41333097
2015 (2), 2014 (1), 2017 (1), R01HL141900 (1)